XTRA:93M

Stock Analysis Report

Executive Summary

MPH Health Care AG operates in the healthcare market in Germany.

Snowflake

Fundamentals

Mediocre balance sheet and slightly overvalued.

Share Price & News

How has MPH Health Care's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.1%

93M

-1.4%

DE Pharmaceuticals

1.7%

DE Market


1 Year Return

-14.4%

93M

2.9%

DE Pharmaceuticals

7.2%

DE Market

Return vs Industry: 93M underperformed the German Pharmaceuticals industry which returned 2.9% over the past year.

Return vs Market: 93M underperformed the German Market which returned 7.2% over the past year.


Shareholder returns

93MIndustryMarket
7 Day-2.1%-1.4%1.7%
30 Day-1.1%-1.8%2.4%
90 Day-0.8%8.8%2.3%
1 Year-9.6%-14.4%6.4%2.9%10.6%7.2%
3 Year21.5%7.2%32.6%17.7%18.4%8.1%
5 Year115.9%72.7%32.5%10.5%42.3%22.9%

Price Volatility Vs. Market

How volatile is MPH Health Care's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MPH Health Care undervalued compared to its fair value and its price relative to the market?

13.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 93M (€3.73) is trading below our estimate of fair value (€4.33)

Significantly Below Fair Value: 93M is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: 93M is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: 93M is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 93M's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 93M is good value based on its PB Ratio (0.6x) compared to the DE Pharmaceuticals industry average (2x).


Next Steps

Future Growth

How is MPH Health Care forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

67.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 93M is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 93M is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 93M is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 93M's revenue (50.6% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: 93M's revenue (50.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 93M's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has MPH Health Care performed over the past 5 years?

3.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 93M is unprofitable, but has reduced losses over the past 5 years at a rate of 3.8% per year.

Accelerating Growth: Unable to compare 93M's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 93M is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.9%).


Return on Equity

High ROE: 93M has a negative Return on Equity (-14.8%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: 93M is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: 93M is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is MPH Health Care's financial position?


Financial Position Analysis

Short Term Liabilities: 93M's short term assets (€9.9M) exceeds its short term liabilities (€8.8M)

Long Term Liabilities: 93M's short term assets (9.9M) do not cover its long term liabilities (16.4M)


Debt to Equity History and Analysis

Debt Level: 93M's debt to equity ratio (5.6%) is considered satisfactory

Reducing Debt: 93M's debt to equity ratio has reduced from 41.6% to 5.6% over the past 5 years.

Debt Coverage: 93M's debt is not well covered by operating cash flow (5%).

Interest Coverage: Insufficient data to determine if 93M's interest payments on its debt are well covered by EBIT.


Balance Sheet

Inventory Level: 93M has a low level of unsold assets or inventory.

Debt Coverage by Assets: 93M's debt is not covered by short term assets (assets are 0.7x debt).


Next Steps

Dividend

What is MPH Health Care's current dividend yield, its reliability and sustainability?

5.36%

Current Dividend Yield


Dividend Yield vs Market

company5.4%marketbottom25%1.5%markettop25%3.8%industryaverage3.0%forecastin3Years5.5%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: 93M's dividend (5.36%) is higher than the bottom 25% of dividend payers in the German market (1.48%).

High Dividend: 93M's dividend (5.36%) is in the top 25% of dividend payers in the German market (3.83%)

Stable Dividend: Whilst dividend payments have been stable, 93M has been paying a dividend for less than 10 years.

Growing Dividend: 93M's dividend payments have increased, but the company has only paid a dividend for 4 years.


Current Payout to Shareholders

Dividend Coverage: 93M is paying a dividend but the company is unprofitable.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of MPH Health Care's salary, the management and board of directors tenure and is there insider trading?


CEO

Patrick Brenske 0

10.8yrs

Tenure

0

Mr. Patrick Brenske has been the Chief Executive Officer of MPH Mittelständische Pharma Holding AG since January 23, 2009 and has been its Member of Management Board since 2009. Mr. Brenske serves as Chief ...


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Patrick Brenske

    CEO & Member of Management Board

    • Tenure: 10.8yrs

Board Members

  • Ulrich Wandschneider (58yo)

    Deputy Chairman of Supervisory Board

    • Tenure: 2.1yrs
  • Sabine Meck (64yo)

    Member of Supervisory Board

    • Tenure: 0yrs
  • Andrea Grosse (54yo)

    Chairwoman of Supervisory Board

    • Tenure: 9.6yrs

Company Information

MPH Health Care AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MPH Health Care AG
  • Ticker: 93M
  • Exchange: XTRA
  • Founded: 2008
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €159.696m
  • Shares outstanding: 42.81m
  • Website: https://www.mph-ag.de

Number of Employees


Location

  • MPH Health Care AG
  • Grünauer Strasse 5
  • Berlin
  • Berlin
  • 12557
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
93MDB (Deutsche Boerse AG)YesCommon StockDEEURSep 2014
93MXTRA (XETRA Trading Platform)YesCommon StockDEEURSep 2014
93MDBATS-CHIXE (BATS 'Chi-X Europe')YesCommon StockGBEURSep 2014
0W1QLSE (London Stock Exchange)YesCommon StockGBEURSep 2014

Biography

MPH Health Care AG operates in the healthcare market in Germany. It produces medicinal products for the therapies of cancer, HIV, and other chronic diseases. The company also offers medical aesthetic treat ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 21:52
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.